SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, Colorado. The two presentations will highlight topics on new research findings on BRIMOCHOL™ PF, the company’s lead product candidate for the treatment of presbyopia, and preclinical data on an early-stage drug candidate for corneal wound healing.
“We are pleased to share these scientific findings with the ophthalmic research community at ARVO 2022,” said Rhett Schiffman, M.D., M.S., M.H.S.A., co-founder, chief medical officer and head of research and development at Visus Therapeutics. “Our non-clinical work with BRIMOCHOL PF demonstrating additive effects of brimonidine on the pharmacokinetics and pharmacodynamics of carbachol proved predictive of our clinical results showing contribution of elements in our Phase 2 study. In addition, our studies of histatin in non-clinical models have generated previously unrecognized insights into the potentially broad clinical utility in managing acute and chronic conditions of all layers of the cornea.”
The schedule of scientific presentations is as follows:
-
Paper Title: Histatin Improves Corneal Wound Healing in a Rabbit Model of Surgical Keratectomy
- Date: Monday, May 2, 2022
- Time: 10:00 a.m. -- 10:17 a.m. Mountain Time
- Location: 2A/3A Mile High Ballroom
- Presenter: James Burke, Visus Therapeutics
-
Poster Title: Nonclinical Pharmacokinetics and Pharmacodynamics of Brimochol, a Combination Product for the Treatment of Presbyopia
- Date: Monday, May 2, 2022
- Time: 12:30 p.m. -- 2:30 p.m. Mountain Time
- Location: Posterboard Number 1819-F0435
- Presenter: Rozemarijn Verhoeven, MTox, Little Creek Research
About Presbyopia
Presbyopia is the loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins when adults are in their 40s and becomes almost universal by age 50.1 Presbyopia impacts billions of people globally with approximately 128 million adults affected in the U.S. alone.2,3 Reading glasses are the most common solution for near-vision correction. However, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons.
About Visus Therapeutics
With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing a novel, pupil-modulating formulation designed to be a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration. For more information, visit: www.visustx.com and follow us on LinkedIn, Twitter (@VisusTx) and Instagram.
1 U.S. Census Bureau. Retrieved September 7, 2019 from http://www.census.gov.
2 Zebardast et al. The Prevalence and Demographic Associations of Presenting Near-Vision Impairment Among Adults Living in the United States. Am J Ophthalmol. 2017;174:134-144.
3 U.S. Census Bureau. Table 9. Washington: Population Division. 2014.
